Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2024 01:00 ET | Source: NMD Pharma

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
March 21, 2024 07:00 ET | Source: NMD Pharma

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
March 21, 2024 02:00 ET | Source: NMD Pharma

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
March 01, 2024 14:00 ET | Source: NMD Pharma

NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences

NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences ClC-1 is a chloride ion channel specifically expressed...
October 03, 2023 07:00 ET | Source: NMD Pharma

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...
October 03, 2023 01:00 ET | Source: NMD Pharma

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...
September 08, 2023 07:00 ET | Source: NMD Pharma

NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association

NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association NMD Pharma to host a satellite symposium* at the...
June 20, 2023 07:00 ET | Source: NMD Pharma

NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2

NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...
June 20, 2023 01:00 ET | Source: NMD Pharma

NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2

NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...
June 01, 2023 07:00 ET | Source: NMD Pharma

NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy

Daniel Brennan brings over 25 years of strategic commercial experience leading public and private rare disease and CNS biopharma companies Aarhus, Denmark, 1 June 2023 – NMD Pharma A/S, a...